Search Results for “NHS” – Page 8 – media

NIHR and Diabetes UK invest nearly £3m to prevent and treat diabetes distress

The National Institute for Health and Care Research (NIHR) and Diabetes UK have partnered, investing nearly £3m, to develop research to treat and prevent type 1 diabetes (T1D) distress. The new funding, awarded to Professor Jackie Sturt at King’s College London, will help to test a new programme known as ‘D-Stress’ to help tackle the overwhelming burden for adults living with the chronic condition. According to Diabetes UK, around 4.4 million people in the UK are living with diabetes, a metabolic disease characterised by elevated levels of blood glucose. Occurring when the pancreas does not produce insulin or makes very little insulin, T1D accounts for approximately 10% of diabetes cases in the UK and almost 50% of adults living with the condition experience high levels of diabetes distress. The new programme aims to deliver care within the NHS for the detection, prevention and management of T1D in adults and will ...
- Source: drugdu
- 77
- July 18, 2024
New policy review reveals ten cancer challenges facing new UK government

Macmillan Cancer Support estimates that cancer affects over three million people in the UK A new policy review produced by cancer doctors and experts from across the UK, including King’s College London (KCL), has revealed the ten biggest cancer challenges facing the new UK government. Published in the Lancet Oncology, the review highlights the time-critical issues impacting the delivery of cancer care services by the NHS, which should be urgently addressed via a comprehensive national cancer control plan. It is estimated that there are more than three million people living in the UK with cancer, according to Macmillan Cancer Support, with breast cancer being the most prevalent, accounting for more than 55,000 people. The authors said that the NHS in the UK is behind other countries and, if not prioritised, could add additional strain to the healthcare system, widen social inequality and weaken economic recovery. The review highlighted several ongoing ...
- Source: drugdu
- 71
- July 16, 2024
NICE recommends Ebglyss for atopic dermatitis patients

England’s National Institute for Health and Care Excellence (Nice) has recommended Almirall’s Ebglyss (lebrikizumab) for patients with moderate to severe atopic dermatitis, giving NHS patients another biological therapy option. In line with NICE guidelines, the NHS will now have 90 days to make the treatment available to patients. Patients over 12 years of age who have not responded to or are not able to take systemic immunosuppressants will be eligible for the therapy, as per a 10 July press release. Monoclonal antibody Ebgylss will join Sanofi / Regeneron’s Dupixent (dupilumab) and Leo Pharma’s Adbry (tralokinumab) as interleukin-targeting options for treating the skin condition. The Janus kinase (JAK) inhibitors Cibinqo (abrocitinib), Olumiant (baricitinib), and Rinvoq (upadacitinib) developed by Pfizer, Eli Lilly, and AbbVie, respectively, are also recommended by NICE. Atopic dermatitis, also known as atopic eczema, is an inflammatory skin condition characterised by intense itching. It has an estimated prevalence of ...
- Source: drugdu
- 61
- July 12, 2024
Institutions to lead £1.7m-funded network to support people at risk of dementia

The neurodegenerative condition currently affects more than 944,000 people in the UK University College London (UCL) and the University of Exeter are set to co-lead a new national Dementia Network Plus initiative supported by more than £1.7m in funding. The Sustainable Prevention, Innovation and Involvement NETwork (SPIINNET) will help to reduce dementia risk and improve people’s experiences of living with dementia by supporting new projects and engaging with communities. Affecting more than 944,000 people in the UK, dementia is a neurodegenerative condition that affects the ability to remember, think or make decisions in everyday life. The new network will combine researchers from 14 universities with specialist organisations, including King’s College London, the University of Plymouth, Bangor, Cardiff Metropolitan, East Anglia, Northampton, Nottingham, Oxford, Southampton, Stirling, Strathclyde, Sunderland and Worcestershire. SPIINNET aims to utilise existing networks and umbrella organisations to deliver a programme to create connections between the experience, knowledge and ...
- Source: drugdu
- 93
- July 12, 2024
Coloplast launches digital leakage notification system Heylo for stoma patients

More than 176,000 people in the UK are living with a stoma, according to NHS data Coloplast has announced the launch of its world-first digital leakage notification system, Heylo, to benefit patients living with a stoma. The new system is now available through the NHS to help alleviate the physical and mental burden of leakage in patients living with a stoma, following an individual consultation and assessment of leakage anxiety. According to NHS data, more than 176,000 people in the UK are living with a stoma, an opening on the abdomen that can be connected to either the digestive or urinary system to remove waste from the body. The most common conditions that can result in stoma surgery include colorectal cancer, bladder cancer, ulcerative colitis, Crohn’s disease and accidental injury. For most patients, leakage of a stoma is currently the biggest challenge, with 92% of people worrying about leakage, impacting ...
- Source: drugdu
- 67
- July 10, 2024
New Labour government backs pharma reform in UK

“Change begins now,” said the UK’s new prime minister, Sir Keir Starmer, in his 5 July victory speech. Ending the 14-year Conservative party reign, the Labour Party has pledged to bolster the UK pharmaceutical sector through increased investment and regulatory action. Starmer’s government is expected to appoint cabinet members in the coming days while junior ministers will be announced today and early into next week. The new members of parliament (MPs) will soon be sworn in from 9 to 11 July. In his final speech as prime minister, Conservative Party leader Rishi Sunak hailed his party’s work to achieve a decreased inflation rate and implement the Windsor Framework for trade in and out of Northern Ireland. However, in a 5 July speech, Starmer said: “Our work is urgent – and we begin it today.” The Labour Party has already promised extensive change to the UK’s life sciences sector, setting forth ...
- Source: drugdu
- 76
- July 9, 2024
Researchers find whole genome sequencing improves care for paediatric cancer

Affecting around 3,755 young people in the UK every year, leukaemia is the most commonly diagnosed cancer in children Researchers from the Wellcome Sanger Institute, Cambridge University Hospitals NHS Trust, Great Ormond Street Hospital and the University of Cambridge have revealed that whole genome sequencing (WGS) can improve the clinical care of children with cancer. Published in Nature Medicine, the study showed that cutting-edge genomic testing could improve the management of care in real-time while providing more benefits compared to all other current tests combined. Every year, around 3,755 young people are diagnosed with cancer in the UK, with some of the most prevalent childhood cancers including lymphoma, muscle or bone cancers, neuroblastoma and leukaemia, which is the most commonly diagnosed cancer in children. WGS is a single test that provides a complete readout of the tumour’s entire genetic code while identifying every single cancer-causing mutation. Researchers, for the first ...
- Source: drugdu
- 94
- July 4, 2024
UK dementia organisations publish new manifesto ahead of general election

Alzheimer’s Society, Dementia UK, Alzheimer’s Research UK, the UK Dementia Research Institute (UK DRI) and Alzheimer Scotland have collaborated to create a new manifesto for dementia, ahead of the 2024 general election (4 July). The new manifesto, ‘Dementia: a manifesto’, calls on the next UK government to make dementia a key health priority in the UK. Affecting 982,000 people in the UK, dementia is a term for the impaired ability to remember, think or make decisions in day-to-day life. There is currently no cure available and the care and treatment options that currently exist for patients living with the neurodegenerative disease are often disjointed, inaccessible and inadequate. The new manifestos call on the next UK government to better understand how to prevent, reduce and delay dementia; increase access to diagnosis and treatment; help people living with dementia navigate support groups; create a care system that works for everyone; and invest ...
- Source: drugdu
- 105
- June 27, 2024
New paediatric blood test to prevent sudden death from hereditary heart condition

Hypertrophic cardiomyopathy is a rare condition that affects up to 1,000 children in the UK Researchers from University College London (UCL) and Great Ormond Street Hospital have developed a new blood test that could identify children with a potentially fatal, hereditary heart condition. The research, co-funded by LifeArc and Action Medical Research, was published in the journal Circulation: Genomics and Precision Medicine. In the UK, up to 1,000 children are living with hypertrophic cardiomyopathy (HCM), a rare hereditary condition that causes the thickening of the heart muscle. Over time, the heart can no longer take in or pump out enough blood to supply the body’s needs, which can cause sudden death in children and young people. Results from the study showed that the new test successfully acted as a marker for HCM. Juan Pablo Kaski, professor of paediatric inherited cardiovascular medicine, UCL Institute of Cardiovascular Science and consultant cardiologist at ...
- Source: drugdu
- 123
- June 13, 2024
DNA Spit Test More Accurate At Identifying Future Prostate Cancer Risk

Currently, the prostate-specific antigen (PSA) test is widely used to identify men who are at an increased risk of prostate cancer based on factors like age and ethnicity, as well as those showing symptoms. Elevated PSA levels may indicate prostate cancer, prompting further investigations such as MRI scans, biopsies, and treatments. However, the PSA test often results in false positives—incorrectly indicating prostate cancer in three out of four instances. It also detects cancers that grow so slowly they are unlikely to pose a significant health threat, leading to potentially unnecessary medical procedures. Now, a saliva-based test that individuals can perform at home has proven better at predicting the risk of developing prostate cancer than the traditional blood test. Researchers from The Institute of Cancer Research (London, UK) and The Royal Marsden NHS Foundation Trust (London, UK) conducted a trial of this innovative DNA test that screens for genetic variants associated ...
- Source: drugdu
- 89
- June 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.